Format

Send to

Choose Destination
Vaccine. 2015 Nov 17;33(46):6277-81. doi: 10.1016/j.vaccine.2015.09.064. Epub 2015 Oct 2.

Pertactin negative Bordetella pertussis demonstrates higher fitness under vaccine selection pressure in a mixed infection model.

Author information

1
School of Biotechnology and Biomolecular Sciences, University of New South Wales, Sydney, New South Wales, Australia.
2
Pathology and Laboratory Medicine, University of Western Australia, Perth, Western Australia, Australia.
3
Centre for Infectious Diseases and Microbiology-Public Health, Institute of Clinical Pathology and Medical Research-Pathology West, Westmead Hospital, New South Wales, Australia; Marie Bashir Institute for Infectious Diseases and Biosecurity, University of Sydney, New South Wales, Australia.
4
National Centre for Immunisation Research and Surveillance, Children's Hospital at Westmead and University of Sydney, New South Wales, Australia.
5
Vaccinology and Immunology Research Trials Unit, Women's and Children's Hospital and School of Paediatrics and Reproductive Health and Robinson Research Institute, University of Adelaide, South Australia, Australia.
6
School of Biotechnology and Biomolecular Sciences, University of New South Wales, Sydney, New South Wales, Australia. Electronic address: r.lan@unsw.edu.au.

Abstract

Whooping cough or pertussis is a highly infectious respiratory disease in humans caused by Bordetella pertussis. The use of acellular vaccines (ACV) has been associated with the recent resurgence of pertussis in developed countries including Australia despite high vaccination coverage where B. pertussis strains that do not express pertactin (Prn), a key antigenic component of the ACV, have emerged and become prevalent. In this study, we used an in vivo competition assay in mice immunised with ACV and in naïve (control) mice to compare the proportion of colonisation with recent clinical Prn positive and Prn negative B. pertussis strains from Australia. The Prn negative strain colonised the respiratory tract more effectively than the Prn positive strain in immunised mice, out-competing the Prn positive strain by day 3 of infection. However, in control mice, the Prn positive strain out-competed the Prn negative strain. Our findings of greater ability of Prn negative strains to colonise ACV-immunised mice are consistent with reports of selective advantage for these strains in ACV-immunised humans.

KEYWORDS:

Acellular pertussis vaccine; B. pertussis; Mixed infection; Mouse model; Pertactin negative

PMID:
26432908
DOI:
10.1016/j.vaccine.2015.09.064
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center